News

News

December 9, 2008

Immunomedics announces combination therapy of Milatuzumab and Rituximab is active in mantle cell lymphoma models

December 8, 2008

Immunomedics reports initial results from phase I/II study of VELTUZUMAB in Immune Thrombocytopenic Purpura

December 8, 2008

Immunomedics reports preliminary results of Milatuzumab in multiple myeloma study

December 8, 2008

Immunomedics reports preliminary results of Milatuzumab in multiple myeloma study
-- Results From First Trial of Humanized Anti-CD74 Antibody Presented at the 50th Annual Meeting of ASH --

December 2, 2008

Immunomedics to present at 50th ASH annual meeting

November 11, 2008

Immunomedics to present at Lazard Capital Markets

November 7, 2008

Immunomedics announces first quarter fiscal 2009 results

October 14, 2008

Immunomedics announces U.S. patents awarded for CD20 antibody, Veltuzumab, and reagents used in pretargeted imaging and therapies

September 17, 2008

Immunomedics highlights progress with clinical programs at R&D day

September 8, 2008

Immunomedics to host R&D day

August 28, 2008

Immunomedics announces fiscal 2008 results

August 1, 2008

Results with Epratuzumab in children with acute lymphoblastic leukemia published in Journal of Clinical Oncology

July 14, 2008

Immunomedics announces worldwide license and collaboration agreement with Nycomed for Veltuzumab for non-cancer indications

June 18, 2008

Immunomedics announces fractionated pretargeted radioimmunotherapy improves pancreatic cancer therapy in animal model

June 17, 2008

Immunomedics develops novel radiotracer for improved PET imaging of cancer

June 16, 2008

Pretargeting method may improve radioimmunoimaging of cancer immunomedics

June 9, 2008

Immunomedics to present at the Society of Nuclear Medicine 55th annual meeting

June 2, 2008

Immunomedics reports clinical results in lymphoma and metastatic colorectal cancer with radioimmunotherapy (RAIT)

June 2, 2008

North central cancer treatment group presents Phase II study results that Epratuzumab in combination with Rituximab and chemotherapy is active, safe and tolerable in aggressive lymphoma

June 2, 2008

Immunomedics reports high anti-lymphoma potency with Veltuzumab

May 27, 2008

Product candidates being presented at 2008 ASCO annual meeting Immunomedics

May 7, 2008

Immunomedics announces third quarter fiscal 2008 results

April 16, 2008

Immunomedics creates novel cytokine immunoconjugates using dock-and-lock

April 15, 2008

Immunomedics’ Milatuzumab may enhance efficacies of therapeutics for multiple myeloma in preclinical studies

April 14, 2008

Immunomedics reports Veltuzumab enhances radio immunotherapy with Epratuzumab in lymphoma model

April 14, 2008

Immunomedics pretargeting method may improve radio immunotherapy of cancer

April 10, 2008

Immunomedics product candidates being presented at 2008 American Association for Cancer Research annual meeting

April 9, 2008

Immunomedics announces results in lymphoma therapy with Veltuzumab administered subcutaneously

April 8, 2008

Immunomedics awarded U.S. patent for use of anti-CD74 immunoconjugates to enhance efficacy of cancer and infectious disease vaccines

March 20, 2008

Immunomedics develops new immunoconjugates for targeted chemotherapy of pancreatic and other cancers

March 18, 2008

Immunomedics’ Milatuzumab receives FDA orphan drug designation for therapy of multiple myeloma

February 7, 2008

Immunomedics announces second quarter fiscal 2008 results

February 4, 2008

Immunomedics announces first patient dosing of Veltuzumab, resulting in a complete response, in immune thrombocytopenic purpur

January 8, 2008

Immunomedics awarded U.S. patent for internalizing anti-CD74 antibodies and methods of use